Literature DB >> 26983851

Men with severe hemophilia in the United States: birth cohort analysis of a large national database.

Marshall A Mazepa1, Paul E Monahan2, Judith R Baker3, Brenda K Riske4, J Michael Soucie5.   

Abstract

The availability of longitudinal data collected prospectively from 1998 to 2011 at federally funded US hemophilia treatment centers provided an opportunity to construct a descriptive analysis of how outcomes of men with severe hemophilia have been altered by the incremental advances and setbacks in hemophilia care in the last 50 years in the United States. This surveillance collaboration with the US Centers for Disease Control and Prevention assembled the largest uniformly examined population with severe hemophilia (n = 4899 men with severe factor VIII and IX deficiency). To address the heterogeneity of this population, 4 successive birth cohorts, differentially affected by eras of hemophilia care, were examined separately in regard to demographics, complications of hemophilia and its treatment, and mortality. Severely affected men in each birth cohort were compared also with the corresponding mild hemophilia birth cohorts (n = 2587 men total) to control for outcomes that might be attributable to aging and environment independent of severely defective hemostasis. The analysis demonstrates improving access to standard of care therapy, correlating the proportion of men on prophylactic factor replacement and reduced bleeding frequency for the youngest men. Frequent bleeding persisted in one third to one half of men across all ages, however, and the disability gap between severe and mild hemophilia did not narrow. The greatest cause of death was liver failure, but attempted anti-hepatitis C virus therapy and cure were low. The study suggests a continued need for national surveillance to monitor and inform hemophilia interventions and outcomes.

Entities:  

Mesh:

Year:  2016        PMID: 26983851      PMCID: PMC4911863          DOI: 10.1182/blood-2015-10-675140

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

Review 1.  The natural evolution of haemophilia care: developing and sustaining comprehensive care globally.

Authors:  B L Evatt
Journal:  Haemophilia       Date:  2006-07       Impact factor: 4.287

2.  Moving beyond access: achieving equity in state health care reform.

Authors:  Brian D Smedley
Journal:  Health Aff (Millwood)       Date:  2008 Mar-Apr       Impact factor: 6.301

3.  Definitions in hemophilia: communication from the SSC of the ISTH.

Authors:  V S Blanchette; N S Key; L R Ljung; M J Manco-Johnson; H M van den Berg; A Srivastava
Journal:  J Thromb Haemost       Date:  2014-09-03       Impact factor: 5.824

4.  Delivery of care to hemophilic children: home care versus hospitalization.

Authors:  H Strawczynski; A Stachewitsch; G Morgenstern; M E Shaw
Journal:  Pediatrics       Date:  1973-06       Impact factor: 7.124

5.  A model for a regional system of care to promote the health and well-being of people with rare chronic genetic disorders.

Authors:  Judith R Baker; Sally O Crudder; Brenda Riske; Val Bias; Ann Forsberg
Journal:  Am J Public Health       Date:  2005-09-29       Impact factor: 9.308

6.  Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

Authors:  Jenny Goudemand; Chantal Rothschild; Virginie Demiguel; Christine Vinciguerrat; Thierry Lambert; Hervé Chambost; Annie Borel-Derlon; Ségolène Claeyssens; Yves Laurian; Thierry Calvez
Journal:  Blood       Date:  2005-09-15       Impact factor: 22.113

Review 7.  Home management of haemophilia.

Authors:  J M Teitel; D Barnard; S Israels; D Lillicrap; M-C Poon; J Sek
Journal:  Haemophilia       Date:  2004-03       Impact factor: 4.287

8.  Clinical outcomes after transfusion-associated hepatitis C.

Authors:  M J Tong; N S el-Farra; A R Reikes; R L Co
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

9.  Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

Authors:  Mark S Sulkowski; David F Gardiner; Maribel Rodriguez-Torres; K Rajender Reddy; Tarek Hassanein; Ira Jacobson; Eric Lawitz; Anna S Lok; Federico Hinestrosa; Paul J Thuluvath; Howard Schwartz; David R Nelson; Gregory T Everson; Timothy Eley; Megan Wind-Rotolo; Shu-Pang Huang; Min Gao; Dennis Hernandez; Fiona McPhee; Diane Sherman; Robert Hindes; William Symonds; Claudio Pasquinelli; Dennis M Grasela
Journal:  N Engl J Med       Date:  2014-01-16       Impact factor: 91.245

10.  Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

Authors:  Kris V Kowdley; Eric Lawitz; Fred Poordad; Daniel E Cohen; David R Nelson; Stefan Zeuzem; Gregory T Everson; Paul Kwo; Graham R Foster; Mark S Sulkowski; Wangang Xie; Tami Pilot-Matias; George Liossis; Lois Larsen; Amit Khatri; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-01-16       Impact factor: 91.245

View more
  35 in total

Review 1.  Gene therapy for hemophilia: what does the future hold?

Authors:  Bhavya S Doshi; Valder R Arruda
Journal:  Ther Adv Hematol       Date:  2018-08-27

Review 2.  Treatment Options in Hemophilia.

Authors:  Wolfgang Miesbach; Joachim Schwäble; Markus M Müller; Erhard Seifried
Journal:  Dtsch Arztebl Int       Date:  2019-11-22       Impact factor: 5.594

Review 3.  Hemophilia gene therapy comes of age.

Authors:  Lindsey A George
Journal:  Blood Adv       Date:  2017-12-08

4.  Differences in bleeding phenotype and provider interventions in postmenarchal adolescents when compared to adult women with bleeding disorders and heavy menstrual bleeding.

Authors:  L V Srivaths; Q C Zhang; V R Byams; J E Dietrich; A H James; P A Kouides; R Kulkarni
Journal:  Haemophilia       Date:  2017-09-05       Impact factor: 4.287

Review 5.  Hemophilia gene therapy comes of age.

Authors:  Lindsey A George
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

6.  Gene Therapy for Inherited Bleeding Disorders.

Authors:  Valder R Arruda; Jesse Weber; Benjamin J Samelson-Jones
Journal:  Semin Thromb Hemost       Date:  2021-02-26       Impact factor: 4.180

7.  Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.

Authors:  Lindsey A George; Spencer K Sullivan; Adam Giermasz; John E J Rasko; Benjamin J Samelson-Jones; Jonathan Ducore; Adam Cuker; Lisa M Sullivan; Suvankar Majumdar; Jerome Teitel; Catherine E McGuinn; Margaret V Ragni; Alvin Y Luk; Daniel Hui; J Fraser Wright; Yifeng Chen; Yun Liu; Katie Wachtel; Angela Winters; Stefan Tiefenbacher; Valder R Arruda; Johannes C M van der Loo; Olga Zelenaia; Daniel Takefman; Marcus E Carr; Linda B Couto; Xavier M Anguela; Katherine A High
Journal:  N Engl J Med       Date:  2017-12-07       Impact factor: 91.245

8.  Inhibitors and mortality in persons with nonsevere hemophilia A in the United States.

Authors:  Ming Y Lim; Dunlei Cheng; Michael Recht; Christine L Kempton; Nigel S Key
Journal:  Blood Adv       Date:  2020-10-13

9.  Gene therapy in hemophilia A: a cost-effectiveness analysis.

Authors:  Nicoletta Machin; Margaret V Ragni; Kenneth J Smith
Journal:  Blood Adv       Date:  2018-07-24

10.  A cross-sectional analysis of cardiovascular disease in the hemophilia population.

Authors:  Suman L Sood; Dunlei Cheng; Margaret Ragni; Craig M Kessler; Doris Quon; Amy D Shapiro; Nigel S Key; Marilyn J Manco-Johnson; Adam Cuker; Christine Kempton; Tzu-Fei Wang; M Elaine Eyster; Philip Kuriakose; Annette von Drygalski; Joan Cox Gill; Allison Wheeler; Peter Kouides; Miguel A Escobar; Cindy Leissinger; Sarah Galdzicka; Marshall Corson; Crystal Watson; Barbara A Konkle
Journal:  Blood Adv       Date:  2018-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.